Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarrays

Journal of Pathology

Volumn 200, Issue 5, 2003, Pages 610-619

  Leversha, M A ^a,b,c   Fielding, P ^a,b,d   Watson, S ^a,b   Gosney, J R ^b   Field, J K ^a,b  

^a Lung Cancer Research   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Immunohistochemistry; Lung cancer; p16; p53; Paraffin; pRB; Tissue microarrays

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; TISSUE SECTION; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0042023334     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1374     Document Type: Article

References (36)

1. Quinn M, Babb P, Brock A, Kirby E, Jones J. Cancer Trends in England and Wales, 1950-1999. Office for National Statistics: London, 2001.
2. Youngson J, Williams E. Incidence of Lung Cancer in Merseyside and Cheshire (1989-1993). Report. Merseyside and Cheshire Cancer Registry: Liverpool, 1995.
3. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4: 844-847.
4. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999; 118: 1136-1152.
5. Liloglou T, Ross H, Prime W, et al. p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. Br J Cancer 1997; 75: 1119-1124.
6. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999; 5: 791-800.
7. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662.
8. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-1975.
9. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000; 31: 406-414.
10. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157: 787-794.
11. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.
12. Gillett CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000; 192: 549-553.
13. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001; 158: 1245-1251.
14. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-2256.
15. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 1994; 51: 544-551.
16. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996; 2: 1169-1176.
17. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51-56.
18. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 1996; 178: 53-58.
19. Kinoshita I, Dosaka-Akita H, Mishina T, et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996; 56: 5557-5562.
20. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56: 3415-3420.
21. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3: 1051-1058.
22. Betticher DC, White GR, Vonlanthen S, et al. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 1997; 74: 556-562.
23. Marchetti A, Doglioni C, Barbareschi M, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998; 75: 187-192.
24. Taga S, Osaki T, Ohgami A, et al. Prognostic value of the immunohistochemical detection of p16INK4 expression in non-small cell lung carcinoma. Cancer 1997; 80: 389-395.
25. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 1998; 153: 1749-1765.
26. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998; 79: 215-220.
27. Tanaka H, Fujii Y, Hirabayashi H, et al. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 1998; 79: 111-115.
28. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188: 351-360.
29. Lee YC, Chang YL, Luh SP, Lee JM, Chen JS. Significance of p53 and Rb protein expression in surgically treated non-small cell lung cancers. Ann Thorac Surg 1999; 68: 343-347.
30. Malusecka E, Zborek A, Krzyzowska-Gruca S. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Folia Histochem Cytobiol 1999; 37: 19-24.
31. Chen J, Chen Y, Chen C, Wang Y. Loss of p 16 and/or pRb protein expression in NSCLC. An immunohistochemical and prognostic study. Lung Cancer 2001; 31: 163-170.
32. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996; 65: 442-445.
33. D'Amico TA, Aloia TA, Moore MB, et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 2000; 69: 882-886.
34. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991; 51: 2735-2739.
35. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, Roy JE, Koh J, Louis DN. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 1999; 79: 1137-1143.
36. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001; 81: 1331-1338.